As December comes to an end, two events will influence MannKind (MNKD) share price in the near term: (1) the MidCap December $27 million trailing 12-month net revenue, and (2) the expiration of 23.3 million warrants exercisable at a price of $1.60. These two events are offsetting keeping share price within a tight trading range through the remaining year.
In my last article, I postulated MannKind missed MidCap's November's $25.5 million net revenue requirement. My model estimated net revenue at $24.3 million that includes a shipment of Afrezza to Brazilian partner Biomm. Commentary